Literature DB >> 22099049

Repeat brachytherapy for patients with residual or recurrent tumors of oral cavity.

Ryo-Ichi Yoshimura1, Hitoshi Shibuya, Keiji Hayashi, Keiko Nakagawa, Kazuma Toda, Hiroshi Watanabe, Atushi Kaida, Masahiko Miura.   

Abstract

PURPOSE: To analyze data from patients receiving repeat brachytherapy (re-BT) for the treatment of residual or recurrent tumor in the oral cavity. METHODS AND MATERIALS: Between January 2003 and December 2007, 62 patients who had undergone definitive BT as an initial treatment of oral cancer subsequently underwent re-BT for the treatment of residual or recurrent tumors at the diagnostic radiology and oncology department (Tokyo Medical and Dental University Hospital). Re-BT was performed 0.9-73 months (median, 5.7) after the initial BT. Au-198 grains were used as the re-BT source in all 62 patients, and an area of 0.8-6.3 cm(2) (median, 3.1) was permanently irradiated with 60-110 Gy (median, 83) according to the system of Paterson-Parker.
RESULTS: The 2-year local control and overall survival rate was 53% and 66%, respectively, and local control significantly affected overall survival. Both local control and overall survival were affected by the initial tumor characteristics and the macroscopic appearance of the residual or recurrent tumor. Grade 3 or 4 complications were seen in 5 patients. The incidence of mandibular and mucosal complications was significantly related to a biologic effective dose of α/β of 3 Gy to the surface of the gingiva and mucosa, respectively.
CONCLUSION: Re-BT using Au-198 grains for the treatment of residual or recurrent tumor after definitive BT in the oral cavity is effective and well tolerated.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22099049     DOI: 10.1016/j.ijrobp.2011.09.018

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  Investigating the displacement of radio-active sources during gold-198 grain brachytherapy for hospitalized oral cancer patients.

Authors:  Masaru Konishi; Yuki Takeuchi; Katsumaro Kubo; Nobuki Imano; Ikuno Nishibuchi; Yuji Murakami; Kiichi Shimabukuro; Pongsapak Wongratwanich; Naoya Kakimoto; Yasushi Nagata
Journal:  J Contemp Brachytherapy       Date:  2022-03-23

2.  Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer.

Authors:  Shumei Murakami; Rinus G Verdonschot; Naoya Kakimoto; Iori Sumida; Masateru Fujiwara; Kazuhiko Ogawa; Souhei Furukawa
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.